| Treatment | |
|---|---|
| **Condition** | Wilson Disease [^1] |
| **Inheritance** | Autosomal recessive (ATP7B gene) [^2] |
| **Category** | Genetic/metabolic |
Wilson disease is a rare autosomal recessive genetic disorder caused by mutations in the ATP7B gene, leading to impaired copper metabolism. The ATP7B protein is a copper-transporting ATPase that primarily functions in the liver, where it incorporates copper into ceruloplasmin and excretes excess copper into bile. When ATP7B function is impaired, copper accumulates in the liver, brain, cornea, and other organs, causing hepatic, neurological, and psychiatric manifestations. Treatment focuses on reducing copper accumulation, preventing further damage, and managing symptoms.
¶ Pathophysiology and Treatment Rationale
In healthy individuals, dietary copper is absorbed in the small intestine and transported to the liver, where ATP7B facilitates copper incorporation into ceruloplasmin and biliary excretion. In Wilson disease:
- Impaired biliary copper excretion leads to progressive hepatic copper accumulation
- Free (non-ceruloplasmin-bound) copper increases in the bloodstream
- Copper deposits in the brain (particularly basal ganglia), cornea, and other tissues
- This leads to the characteristic hepatic, neurological, and psychiatric manifestations
The primary objectives of Wilson disease treatment are:
- Remove excess copper — Reduce total body copper burden
- Prevent copper re-accumulation — Maintain negative copper balance
- Treat complications — Manage hepatic, neurological, and psychiatric symptoms
- Monitor for treatment response — Adjust therapy based on clinical and biochemical markers
Penicillamine
- Mechanism: Binds copper and promotes urinary excretion
- Dosage: 250-500 mg orally, 2-4 times daily
- Monitoring: 24-hour urinary copper, liver function tests
- Side effects: Bone marrow suppression, nephrotoxicity, skin reactions
- Note: Less commonly used due to side effect profile; reserve for patients intolerant to other therapies
Trientine
- Mechanism: Chelates copper and promotes excretion
- Dosage: 300-900 mg orally, divided doses
- Advantages over penicillamine: Better tolerability, fewer side effects
- Monitoring: Urinary copper, liver function
- Side effects: GI upset, skin rash (less common than penicillamine)
Zinc Salts (Zinc Acetate, Zinc Gluconate)
- Mechanism: Blocks intestinal copper absorption by inducing metallothionein
- Dosage: 50 mg elemental zinc 3 times daily (150 mg/day total)
- Onset: Slower than chelators (4-6 weeks for effect)
- Advantages: Excellent tolerability, few side effects (GI upset most common)
- Use: First-line for presymptomatic patients, maintenance therapy, or combination with chelators
- Low-copper diet: Avoid organ meats, shellfish, nuts, chocolate, mushrooms
- Water filters: For patients with high copper in drinking water
- Vitamin E: Antioxidant supplementation may help protect liver
- Tremor: Propranolol, clonazepam
- Dyskinesia: Tetrabenazine, dopamine antagonists
- Dystonia: Botulinum toxin, anticholinergics (trihexyphenidyl)
- Seizures: Standard antiepileptic drugs (avoid valproate if possible)
- Depression/Anxiety: SSRIs, anxiolytics
- Psychosis: Atypical antipsychotics (risperidone, quetiapine)
- Behavioral changes: Structured environment, behavioral therapy
- Liver transplantation: For patients with fulminant hepatic failure or end-stage cirrhosis
- Supportive care: Management of portal hypertension, ascites
¶ Monitoring and Follow-Up
| Parameter |
Frequency |
| Liver function tests |
Monthly initially, then every 3-6 months |
| 24-hour urinary copper |
Every 3-6 months |
| Serum non-ceruloplasmin copper |
Every 6 months |
| Neurological examination |
Every 3-6 months |
| Ophthalmologic exam (Kayser-Fleischer rings) |
Annually |
- Continue treatment during pregnancy to prevent maternal and fetal complications
- Zinc is generally preferred during pregnancy
- Reduce chelator doses if possible
- Close monitoring of liver function
- Zinc often first-line for children
- Lower chelator doses with careful monitoring
- Growth and development monitoring essential
- Gene therapy: Experimental approaches to deliver functional ATP7B gene
- Novel chelators: Bis-choline tetrathiomolybdate in clinical trials
- Small molecules: ATP7B-targeting compounds in development
With early diagnosis and adequate treatment, most patients have excellent outcomes. Neurological symptoms may improve over 1-3 years of treatment. Prognosis depends on:
- Age at treatment initiation
- Severity of neurological involvement at diagnosis
- Adherence to therapy
- Degree of liver damage at presentation
- Ferenci P, Wilson disease: Pathogenesis and treatment (2023)
- Weiss KH et al., Chelation therapy in Wilson disease (2022)
- Schilsky ML et al., Zinc therapy for Wilson disease (2022)
- Roberts EA, Schilsky ML, Diagnosis and treatment of Wilson disease (2021)
- Srivastava A et al., Liver transplantation for Wilson disease (2020)
- Ahmadi M et al., Long-term outcome of Wilson disease patients (2022)